Business
While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP-1 asset BT-001 into late-stage development, with two trials planned this year.
FEATURED STORIES
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Shares of Cellectis Therapeutics were up nearly 10% in premarket trading after the company forged a deal with Cytovia Therapeutics to develop immunotherapies based on gene-edited allogeneic CAR T-cells.
Centessa Pharmaceuticals, based in Cambridge, Massachusetts and London, launched what it is calling a “novel asset-centric pharmaceutical company.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.
Biotech investor Neil Woodford is poised for a comeback after a fall from grace two years ago.
A new biotech hotspot could be on the horizon in Oregon thanks to a $500 million gift to the University of Oregon from Nike co-founder Phil Knight, an alumnus of the university.
Eric Poma, chief executive and scientific officer for Molecular Templates, touted the partnership with BMS and its strong oncology franchise.
Josh Smiley’s termination from Eli Lilly for inappropriate communications with employees will cost more than a blow to his reputation.
As part of the Takeda deal, Ensoma will do preclinical research for therapies in up to five rare disease indications, and both companies will work on Investigational New Drug-enabling studies.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Immunai today announced it has received $60 million in Series A funding, bringing its total funding since inception in December 2018 to $80 million.